In the intricate tapestry of the pharmaceutical industry, the year 2024 unfurls as a panorama of uncertainty and opportunity. Amidst the looming threat of economic downturns and the shadow of increased regulatory burdens from the Inflation Reduction Act (IRA), the industry finds itself at the crossroads. The pivotal keyword, “AI opportunities,” weaves through the fabric
